Lung Cancer News

Eribulin Does Not Prolong Overall Survival in Non-small Cell Lung Cancer

Eribulin Does Not Prolong Overall Survival in Non-small Cell Lung Cancer

While eribulin is not superior in prolonging OS compared with the established second- and third-line therapies, it may have a role as a third-line agent.

Proton Beam Therapy Plus Chemotherapy May Provide Benefit in Unresectable Non-small Cell Lung Cancer

Proton Beam Therapy Plus Chemotherapy May Provide Benefit in Unresectable Non-small Cell Lung Cancer

Researchers enrolled 64 patients with unresectable NSCLC to receive concurrent passively scattered PBT and weekly infusions of carboplatin-paclitaxel.

Tremelimumab Does Not Prolong Overall Survival in Malignant Mesothelioma

Tremelimumab Does Not Prolong Overall Survival in Malignant Mesothelioma

Among patients with relapsed malignant mesothelioma, tremelimumab does not improve OS compared with placebo.

Proton-beam Therapy May Be Effective for Limited-stage Small-cell Lung Cancer

Proton-beam Therapy May Be Effective for Limited-stage Small-cell Lung Cancer

With concurrent chemotherapy, proton-beam therapy is safe and may be effective for patients with limited-stage small-cell lung cancer.

TPX-0005 Granted Orphan Drug Designation for Non-small Cell Lung Cancer

TPX-0005 Granted Orphan Drug Designation for Non-small Cell Lung Cancer

The FDA granted orphan drug designation today to TPX-0005 — a small molecule kinase inhibitor — for the treatment of NSCLC with ALK, ROS1, or NTRK rearrangements.

FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC

FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC

The US Food and Drug Administration approved the combination of dabrafenib and trametinib for metastatic non-small cell lung cancer (NSCLC) with a BRAFV600E mutation.

First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC

First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC

Study results suggest that first-line treatment of advanced NSCLC with nivolumab does not prolong PFS or OS compared with chemotherapy, though nivolumab had a better safety profile.

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.

OS Milestone Rate May Be Useful Secondary Endpoint in NSCLC Trials

OS Milestone Rate May Be Useful Secondary Endpoint in NSCLC Trials

The 12-month overall survival milestone rate correlates with OS hazard ratio in trials of metastatic non-small cell lung cancer and could be a valuable secondary endpoint.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Palifosfamide With Platinum Doublet Fails To Prolong Survival in SCLC

Palifosfamide With Platinum Doublet Fails To Prolong Survival in SCLC

The addition of palifosfamide to carboplatin and etoposide failed to prolong survival among patients with extensive-stage small-cell lung cancer.

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.

Vemurafenib Active in BRAFV600-mutant NSCLC

Vemurafenib Active in BRAFV600-mutant NSCLC

Vemurafenib improves outcomes among patients with non-small cell lung cancer with a BRAFV600 mutation.

Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC

Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC

Adaptive escalation of radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with locally advanced non-small cell lung cancer.

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters